IBDEI1NM ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,26414,2)
 ;;=^5138333
 ;;^UTILITY(U,$J,358.3,26415,0)
 ;;=E11.40^^107^1241^10
 ;;^UTILITY(U,$J,358.3,26415,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26415,1,3,0)
 ;;=3^DM Type 2 w/ Diab Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,26415,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,26415,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,26416,0)
 ;;=E11.51^^107^1241^12
 ;;^UTILITY(U,$J,358.3,26416,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26416,1,3,0)
 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,26416,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,26416,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,26417,0)
 ;;=E11.52^^107^1241^11
 ;;^UTILITY(U,$J,358.3,26417,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26417,1,3,0)
 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,26417,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,26417,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,26418,0)
 ;;=E11.620^^107^1241^5
 ;;^UTILITY(U,$J,358.3,26418,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26418,1,3,0)
 ;;=3^DM Type 2 w/ Diab Dermatitis
 ;;^UTILITY(U,$J,358.3,26418,1,4,0)
 ;;=4^E11.620
 ;;^UTILITY(U,$J,358.3,26418,2)
 ;;=^5002655
 ;;^UTILITY(U,$J,358.3,26419,0)
 ;;=E11.36^^107^1241^4
 ;;^UTILITY(U,$J,358.3,26419,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26419,1,3,0)
 ;;=3^DM Type 2 w/ Diab Cataract
 ;;^UTILITY(U,$J,358.3,26419,1,4,0)
 ;;=4^E11.36
 ;;^UTILITY(U,$J,358.3,26419,2)
 ;;=^5002642
 ;;^UTILITY(U,$J,358.3,26420,0)
 ;;=I10.^^107^1242^1
 ;;^UTILITY(U,$J,358.3,26420,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26420,1,3,0)
 ;;=3^Essential/Primary Hypertension
 ;;^UTILITY(U,$J,358.3,26420,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,26420,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,26421,0)
 ;;=I11.0^^107^1242^12
 ;;^UTILITY(U,$J,358.3,26421,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26421,1,3,0)
 ;;=3^Hypertensive Heart Disease w/ Heart Failure
 ;;^UTILITY(U,$J,358.3,26421,1,4,0)
 ;;=4^I11.0
 ;;^UTILITY(U,$J,358.3,26421,2)
 ;;=^5007063
 ;;^UTILITY(U,$J,358.3,26422,0)
 ;;=I11.9^^107^1242^13
 ;;^UTILITY(U,$J,358.3,26422,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26422,1,3,0)
 ;;=3^Hypertensive Heart Disease w/o Heart Failure
 ;;^UTILITY(U,$J,358.3,26422,1,4,0)
 ;;=4^I11.9
 ;;^UTILITY(U,$J,358.3,26422,2)
 ;;=^5007064
 ;;^UTILITY(U,$J,358.3,26423,0)
 ;;=I12.0^^107^1242^5
 ;;^UTILITY(U,$J,358.3,26423,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26423,1,3,0)
 ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
 ;;^UTILITY(U,$J,358.3,26423,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,26423,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,26424,0)
 ;;=I12.9^^107^1242^4
 ;;^UTILITY(U,$J,358.3,26424,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26424,1,3,0)
 ;;=3^Hypertensive CKD w/ Stage 1-4 CKD
 ;;^UTILITY(U,$J,358.3,26424,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,26424,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,26425,0)
 ;;=I13.0^^107^1242^8
 ;;^UTILITY(U,$J,358.3,26425,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26425,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD
 ;;^UTILITY(U,$J,358.3,26425,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,26425,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,26426,0)
 ;;=I13.10^^107^1242^10
 ;;^UTILITY(U,$J,358.3,26426,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26426,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD
 ;;^UTILITY(U,$J,358.3,26426,1,4,0)
 ;;=4^I13.10
